Biotech Values

[DewDiligence]

> CTIC – Do you know why in that [September] pr it says $270 million and in today's pr it says $405 million?<

There’s $15M from an equity purchase, $270M in potential milestones for Xyotax (if NVS elects to exercise its Xyotax option), a $7.5M potential license fee for Pixantrone (if NVS elects to exercises its option), and $104M in potential milestones for Pixantrone (if NVS elects to exercise its options for both Xyotax and Pixantrone). That sums to $396.5M. I don’t know where the other $8.5M (405-396.5) comes from, but it probably doesn’t matter because I think it’s unlikely CTIC will ever see the majority of these milestones. Regards, Dew